Eloxx Pharmaceuticals vs Prime Medicine
ELOX and PRME side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ELOX and PRME compare
Prime Medicine is the larger company, worth 15 times as much as Eloxx Pharmaceuticals ($774M against $53.1M).
Eloxx Pharmaceuticals scores higher on the StockData Score (7 against 5 for Prime Medicine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ELOX | PRME |
|---|---|---|
| Size and price | ||
| Market cap | $53.1M | $774M |
| Share price | $13.15 | $4.27 |
| Change, 1 year | 1195350% | 20.3% |
| Change, 5 years | −97.8% | −79.8% |
| Beta (5Y) | – | 0.43 |
| Employees | 7 | 146 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.1× (better) | 91.8× |
| FCF yield | – | −20.5% |
| Growth | ||
| Revenue growth (TTM) | −100% | – |
| Revenue growth, 5Y average | – | −2.3% |
| Profitability | ||
| Return on equity | −54.3% (better) | −207% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.74 (better) | 1.79 |
| Altman Z-score | −4.40 (better) | −7.06 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 71.8% | 58.8% |
| Held by insiders | 42.6% | 18.6% |
| Short interest, % of float | 2.3% | 19.7% |
Go deeper
- ELOX stock overview
- ELOX income statement
- ELOX valuation and score
- PRME stock overview
- PRME income statement
- PRME valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.